FDA approves $2.59 million gene therapy for SMA
The FDA has approved Itvisma (onasemnogene abeparvovec-brve) to treat children two years and older, teens, and adults living with spinal...
Gene
Gene Therapy Market Size to Worth USD 58.87 Billion Rising
Ottawa, Oct. 08, 2025 (GLOBE NEWSWIRE) -- The global gene therapy market size was valued at USD 9.50 billion in 2024...
Revolutionizing Healthcare: The Booming Global Market for Cell and Gene Therapy Logistics
According to Renub Research Latest Report healthcare landscape is shifting from generalized treatment to personalized medicine, and the cell and...
Exosome Cell and Gene Therapy Market 2026 Drives by Rising
Ottawa, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The exosome cell and gene therapy market is rising due to the growing demand...
CRISPR Technologies for In Vivo and Ex Vivo Gene Editing
Key MessagesWhat Is the Issue?:The first therapeutics based on clustered regularly interspaced short palindromic repeats (CRISPR) technologies are entering the...
Bahrain Leads The Way In Transformative Medical Tourism With Groundbreaking CRISPR Gene Therapy Breakthrough
Home » MEDICAL TOURISM NEWS » Bahrain Leads The Way In Transformative Medical Tourism With Groundbreaking CRISPR Gene Therapy Breakthrough...
Cell and gene therapy market set to grow at 44% CAGR through 2030, reveals GlobalData – Healthcare News
The global cell and gene therapy (CGT) market is poised for exceptional growth at a compound annual growth rate of...
Novartis gene therapy poised to expand SMA treatment landscape – Healthcare News
Novartis has recently announced that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) successfully achieved the primary endpoint in...
Genprex Leadership to Present Gene Therapy Breakthroughs at J.P. Morgan Healthcare Conference
AUSTIN, Texas, Jan. 6, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on...
